Cerity Partners
BCRX icon

Cerity Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cerity Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$759K Buy
75,908
+64,754
+581% +$586K ﹤0.01% 2165
2026
Q1 		$106K Buy
+11,154
New +$86.6K ﹤0.01% 3018
2025
Q4 		– Sell
-25,522
Closed -$194K – 2887
2025
Q3 		$194K Sell
25,522
-3,242
-11% -$27K ﹤0.01% 2511
2025
Q2 		$258K Sell
28,764
-7,646
-21% -$71.2K ﹤0.01% 2230
2025
Q1 		$273K Buy
36,410
+24,418
+204% +$197K ﹤0.01% 2071
2024
Q4 		$90.5K Sell
11,992
-12,708
-51% -$96.5K ﹤0.01% 2344
2024
Q3 		$188K Buy
24,700
+13,066
+112% +$99.3K ﹤0.01% 2335
2024
Q2 		$71.9K Sell
11,634
-738
-6% -$4.07K ﹤0.01% 2146
2024
Q1 		$62.8K Buy
+12,372
New +$69.6K ﹤0.01% 2239

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Cerity Partners's BCRX Position: Q2 2026 in Review

Cerity Partners increased its BioCryst Pharmaceuticals (BCRX) stake by 581% in Q2 2026, buying an estimated $586K and bringing the position to 75,908 shares worth $759K. The position accounts for ﹤0.01% of the portfolio, ranked #2165.

Cerity Partners first reported a position in BCRX in Q1 2024 and has held it in 9 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Cerity Partners held 75,908 shares of BioCryst Pharmaceuticals worth $759K as of Q2 2026.
  • Cerity Partners bought 64,754 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $586K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2165 holding.
  • Cerity Partners first reported a position in BioCryst Pharmaceuticals in Q1 2024 and has held it in 9 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.